CFTR and cystic fibrosis: Despite its suboptimal effects, MCG1516A was able to rescue L206W- and R334W-CFTR processing and function in cell lines and had additive effects with VX-661, suggesting that this combination might be a feasible therapeutic option for individuals with CF having these rare mutants in addition to F508del.